LATEST UPDATES » Vol 22, No 11, November 2018 – The Asian Cancer - War on liver cancer       » 2018 Nobel Prize in Physiology or Medicine winners       » Women more prone to selected chemotherapy side effects       » Tibetan fungus could help fight liver cancer       » Standards for TCM decoction to be applied globally       » RMB200 million donation to build Tsinghua University Biomedical Sciences Building      
Radiation therapy improves tumour response in liver cancer patients
Multi-disciplinary team discovers radiation therapy known as Yttrium-90 radioembolisation (Y90-RE) increases anti-cancer immunity and improves tumour response in liver cancer patients.

Yttrium-90 radioembolisation (Y90-RE), a form of radiation therapy, was discovered by scientists in Singapore, to boost patients’ immune systems to fight hepatocellular carcinoma (HCC), or primary liver cancer. This is in addition to the expected effects of radiotherapy, which is to kill cancer cells directly. Y90-RE enhances the activation of immune cells with anti-tumour activity in patients with HCC.

The research team comprised members from the National Cancer Centre Singapore (NCCS), Translational Immunology Institute (TII), SingHealth Duke-NUS Academic Medical Centre and the Singapore General Hospital (SGH).

Y90-RE is a minimally-invasive radiation treatment that delivers high-energy beta radiation directly to cancer tumours. It is currently being used as treatment for patients with tumours that are too advanced for surgery, liver transplant, or radiofrequency ablation (RFA). Findings of the impact of Y90-RE on the immune system were published in scientific journal Gut in February 2018.

The team looked at 34 patients with intermediate and advanced HCC over two years. They studied specific T-cells populations (immune cells with anti-tumour activity) in the patients’ blood and within the liver cancer after Y90-RE treatment, and found that they significantly increased and remained elevated specifically in patients with sustained response.

Of these 34 patients, 16 patients showed no further tumour progression and seven patients’ cancer tumours shrank sufficiently (downstaged) for subsequent liver resection. These seven patients were compared to another seven patients who had surgery for HCC without being downstaged with Y90-RE.

In another recent publication, the team reported the conclusion of a six-year long, 11-country Asia-Pacific phase-III clinical trial led by NCCS comparing Y90-RE with anti-cancer drug sorafenib in 364 patients. This clinical trial showed that while average survival rates were similar with the two treatment methods, patients treated with Y90-RE had significantly fewer side-effects and better tumour response.

Prof Pierce Chow, Protocol Chair of the phase III trial and also corresponding author of translational research study said, “The combined findings of these two landmark studies suggests the potential combination of immunotherapy with Y90-RE, so as to enhance the efficacy of immunotherapy treatment for patients with liver cancer.” Prof Chow is Senior Consultant, Division of Surgical Oncology at NCCS and Course Director at Duke-NUS Medical School.

In addition to the clinical study, the team will next be looking at developing a prediction tool to determine which patients will benefit most from Y90-RE.

These studies were made possible with funding from the National Medical Research Council Singapore. Sirtex Medical also contributed with a research grant in the phase III clinical trial.

Click here for the complete issue.

news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
Asia Pacific Biotech News

APBN Editorial Calendar 2018
Obesity / Outlook for 2018
Searching for the fountain of youth
Women in Science - Making a difference
Digestive health in the 21st century - Trust your guts
Dental health - The root to good health
Cancer - Therapies and strategies for better patient outcomes
Water management - Technologies for biotech and pharmaceutical industries
Regenerative technology - Meat of the future
Doctor Robot - The digital healthcare revolution
Bones / Breast cancer
Liver health / Top science research nations & institutions
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy